The nurse is caring for a client receiving warfarin. The nurse should educate the client to avoid significantly increasing or decreasing their intake of which food?

A. Hyperglycemia: Fenofibrate primarily affects lipid metabolism and is not commonly associated with causing high blood glucose levels. While monitoring is important in clients with diabetes, hyperglycemia is not a typical adverse effect of this medication.

B. Increased hemoglobin: Fenofibrate does not influence hemoglobin levels. Any changes in hemoglobin are unlikely to be related to fenofibrate therapy and should prompt evaluation for other underlying conditions.

C. Hepatotoxicity: Fenofibrate can cause liver injury, evidenced by elevated liver enzymes or other signs of hepatotoxicity. Monitoring liver function tests before and during therapy is essential to detect adverse effects early and prevent serious liver complications.

D. Fever: Fever is not a recognized adverse effect of fenofibrate. If a client develops fever, other causes such as infection or unrelated inflammatory processes should be investigated rather than attributing it to the medication.

A. "Heparin will help prevent the development of a blood clot.": Heparin is an anticoagulant that works by inhibiting clotting factors, reducing the risk of new clot formation. It does not dissolve existing clots but is essential in preventing progression or formation of additional thrombi.

B. "Heparin will help to stabilize your blood pressure and heart rate.": Heparin does not have effects on cardiovascular parameters such as blood pressure or heart rate. Monitoring vital signs is important during therapy, but the medication’s purpose is anticoagulation, not hemodynamic stabilization.

C. "Heparin will help to break down the existing clot in your leg.": Heparin prevents further clot formation but does not actively dissolve existing thrombi. Thrombolytic medications, not heparin, are used for clot breakdown.

D. "Heparin will help increase the number of platelets in the body.": Heparin can actually decrease platelet count in some cases (heparin-induced thrombocytopenia), so it does not increase platelet levels. Its mechanism is anticoagulation through inhibition of clotting factors, not platelet production.